Tags

Type your tag names separated by a space and hit enter

[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Ned Tijdschr Geneeskd. 2007 Nov 24; 151(47):2615-9.NT

Abstract

--Obesity is an important healthcare issue. --Recent research has led to insights into the role of the endocannabinoid system in the regulation of body weight. --Rimonabant is a CB1-endocannabinoid-receptor antagonist. --Four trials were published recently on the efficacy and safety of rimonabant in the treatment of people with obesity. --When combined with a hypocaloric diet, rimonabant 20 mg/day was more effective than placebo in achieving and maintaining weight loss. In addition, treatment with rimonabant had beneficial effects on insulin resistance, HDL-cholesterol and hypertriglyceridaemia. --There is concern regarding the increased incidence of depression during treatment. --Whether the beneficial effects of rimonabant on weight reduction and cardiovascular risk factors translate into a reduction in cardiovascular morbidity and mortality remains to be established in large phase III trials.

Authors+Show Affiliations

Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Cardiologie. s.m.boekholdt@amc.uva.nlNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review
Comment

Language

dut

PubMed ID

18161262

Citation

Boekholdt, S M., et al. "[The Endocannabinoid System, Overweight, and the CB1-endocannabinoid-receptor Antagonist Rimonabant]." Nederlands Tijdschrift Voor Geneeskunde, vol. 151, no. 47, 2007, pp. 2615-9.
Boekholdt SM, Jukema JW, Peters RJ. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant]. Ned Tijdschr Geneeskd. 2007;151(47):2615-9.
Boekholdt, S. M., Jukema, J. W., & Peters, R. J. (2007). [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant]. Nederlands Tijdschrift Voor Geneeskunde, 151(47), 2615-9.
Boekholdt SM, Jukema JW, Peters RJ. [The Endocannabinoid System, Overweight, and the CB1-endocannabinoid-receptor Antagonist Rimonabant]. Ned Tijdschr Geneeskd. 2007 Nov 24;151(47):2615-9. PubMed PMID: 18161262.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant]. AU - Boekholdt,S M, AU - Jukema,J W, AU - Peters,R J G, PY - 2007/12/29/pubmed PY - 2008/1/30/medline PY - 2007/12/29/entrez SP - 2615 EP - 9 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 151 IS - 47 N2 - --Obesity is an important healthcare issue. --Recent research has led to insights into the role of the endocannabinoid system in the regulation of body weight. --Rimonabant is a CB1-endocannabinoid-receptor antagonist. --Four trials were published recently on the efficacy and safety of rimonabant in the treatment of people with obesity. --When combined with a hypocaloric diet, rimonabant 20 mg/day was more effective than placebo in achieving and maintaining weight loss. In addition, treatment with rimonabant had beneficial effects on insulin resistance, HDL-cholesterol and hypertriglyceridaemia. --There is concern regarding the increased incidence of depression during treatment. --Whether the beneficial effects of rimonabant on weight reduction and cardiovascular risk factors translate into a reduction in cardiovascular morbidity and mortality remains to be established in large phase III trials. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/18161262/[The_endocannabinoid_system_overweight_and_the_CB1_endocannabinoid_receptor_antagonist_rimonabant]_ L2 - https://medlineplus.gov/obesity.html DB - PRIME DP - Unbound Medicine ER -